- Home
- PHAT vs ABX Comparison
PHAT vs ABX Comparison
Compare PHAT & ABX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAT | ABX |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 725.3M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAT | ABX |
|---|---|---|
| Price | $10.66 | $9.12 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | ★ $19.50 | $11.00 |
| AVG Volume (30 Days) | ★ 986.1K | 661.9K |
| Earning Date | 04-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | ★ 2.23% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $175,110,000.00 | N/A |
| Revenue This Year | $92.15 | $14.85 |
| Revenue Next Year | $59.79 | $6.54 |
| P/E Ratio | ★ N/A | $74.88 |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $7.18 |
| 52 Week High | $18.31 | $10.54 |
Technical Indicators
Market Signals| Indicator | PHAT | ABX |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 47.99 |
| Support Level | $10.06 | $8.10 |
| Resistance Level | $12.77 | $10.52 |
| Average True Range (ATR) | 0.68 | 0.47 |
| MACD | 0.10 | -0.15 |
| Stochastic Oscillator | 33.87 | 25.07 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ABX Abacus Global Management Inc. Class A Common Stock
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.